VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

BSH 2018 | An unmet need in CLL: patients failing ibrutinib and idelalisib

Relapse and failure of ibrutinib and idelalisib regimens in chronic lymphocytic leukaemia (CLL) is becoming an increasingly common. Here, Christopher Fox, MBChB(Hons), MRCP FRCPath, of Nottingham University Hospitals NHS Trust, Nottingham, UK, discusses the use of venetoclax for patients who have failed these BTK inhibitors. Venetoclax has proven effective in trials, with high efficacy, response rates, impressive progression-free survival and MRD negativity.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter